Difficulty lifting a cup or writing, and the effort of travelling to have treatment adjusted: these everyday burdens matter to people with Parkinson’s and their families.

This issue covers two developments: wider US availability of a wrist-worn therapy, and a comparison of remote versus hospital-based programming after deep brain stimulation. We explain the potential help and what remains uncertain.

Story 1

A wrist-worn hand-tremor device launches nationwide in the US

🔍 What was announced

Hand tremor does not always happen in the same circumstances. A hand may shake while resting, while holding an arm out, or while lifting a cup. When the tremor occurs matters when considering treatment.

Cala Health announced nationwide US availability of Cala kIQ Plus, a prescription wrist-worn therapy device. Electrodes against the skin stimulate nerves at the wrist. Unlike surgery that implants electrodes in the brain, this delivers stimulation externally at the wrist. The October 6 announcement concerns expanded availability, not a newly granted authorization: clearance had already been announced earlier this year.

The US Food and Drug Administration (FDA) indication for Parkinson’s is temporary relief, after stimulation, of treated-hand tremor while maintaining a posture or moving. Tremor while holding a position is called postural tremorPostural tremor occurs while holding a position; kinetic tremor occurs during movement. These are distinguished from tremor at rest.Learn more; tremor during movement is called kinetic tremor. This indication does not mean the device treats all resting tremor.

Changes from the previous device include three stimulation modes to choose from and calibration at the start of every session. The FDA document specifies a 40-minute session. Although worn like a watch, it is not an ordinary smartwatch health feature: it is a prescription medical device.

A new mode is not the same as proof of greater benefit in Parkinson’s. The new-mode study submitted to the FDA involved 30 people with essential tremorA tremor condition distinct from Parkinson’s, often noticeable when holding a position or moving. Findings in one condition cannot simply be applied to the other.Learn more, not Parkinson’s, over six weeks. Each person tried the three modes in sequence. Its improvement percentages must therefore not be presented as Parkinson’s response rates. Benefit and duration can differ between people; the device is not authorized to slow disease progression.

“The Parkinson’s indication is temporary relief of postural and kinetic hand tremor after stimulation. The updated device adds mode selection and calibration before each session. Its new-mode comparison involved essential tremor, so those results cannot be interpreted as an effect across all people with Parkinson’s.”
— ParkinON summary of the FDA document and manufacturer announcement; not a direct quotation
Read the original (FDA document)

✅ For people with Parkinson’s

The important development is an external treatment option aimed at particular hand tremors, alongside the wider range of medication and surgical approaches. It does not mean everyone with Parkinson’s needs this device or that it replaces medication.

Tell your clinician whether lifting a cup, using cutlery or resting your hand causes difficulty. “Hand tremor” covers different situations. The question to ask before focusing on a product name is which treatment fits the activity that troubles you most.

The verified announcement concerns US prescription supply. Authorization, access and insurance coverage elsewhere have not been established here. Overseas marketing is not a reason to buy or use a device without appropriate clinical advice.

This does not treat Parkinson’s as a whole. It is a US prescription device for temporary relief of certain hand tremors. Local authorization and access need separate confirmation.

🙋 For family and care partners

Add the task that became difficult to “the shaking was bad.” Spilling water while pouring, struggling to bring a spoon to the mouth or having trouble signing a name describes a treatment goal more clearly. Record medication timing if possible.

When product information reports a large improvement percentage, check whether participants had Parkinson’s or another tremor condition. What matters is whether the desired task becomes easier, whether discomfort or adverse effects occur, and how long any relief lasts.

An open laptop, notebook and pen on a table
Story 2

Can DBS programming continue remotely after surgery?

🔍 What the study found

Deep brain stimulation (DBS)Treatment using electrodes implanted in specific brain areas to help control symptoms. Programming and follow-up remain necessary after surgery.Learn more is not finished when the device is implanted. Clinicians adjust stimulation settings in response to symptoms and treatment effects. Repeated follow-up trips can be burdensome when a hospital is far away or travel is difficult.

Researchers at six German centres compared whether remote follow-up programming could preserve motor control relative to in-person programming. Fifty-two adults who had recently undergone DBS implantation participated. Results were published in Movement Disorders on October 23.

Everyone first received initial programming in hospital. Participants were then assigned to in-person or secure-platform remote follow-up by random allocationAllocation to comparison groups by chance, to reduce differences unrelated to treatment. It does not itself make a study large or long term.Learn more. This was not treatment entirely at home from the outset, nor people with Parkinson’s changing settings on their own.

The main outcome was a motor-symptom score at 90 days, assessed with medication and stimulation both on. The reported per-protocol analysis included 48 participants: 26 in conventional care and 22 in remote programming. The reported between-group median difference was −2.5 points, with a 95% confidence intervalAn interval showing uncertainty around an estimate under the analysis assumptions. It is not a personal probability of treatment success.Learn more of −9.0 to 2.0. The key was meeting a prespecified comparison criterion, not showing one group was definitely better.

The question was whether remote programming was not worse than in-person programming beyond an agreed margin, rather than whether it was superior. The margin was five points, and the result met this noninferiorityTesting whether an approach is not worse than a comparator beyond a prespecified margin. This does not establish equivalence or superiority.Learn more criterion. It does not prove that the two approaches are identical or that remote care is better.

Other clinical and participant-reported outcomes were broadly comparable. Serious adverse events occurred at similar frequencies, and there were no deaths. However, this was 52 participants and the first three months, and participants knew their care arrangement. Longer-term safety and applicability to all people receiving DBS need further study. The abstract does not support numerical claims about visits or money saved.

“All participants had initial in-person programming. During the first three months, remote follow-up motor outcomes were not worse than conventional follow-up beyond the prespecified margin. This short-term comparison does not establish long-term safety or show that all in-person care can be replaced.”
— ParkinON summary of the Movement Disorders abstract; not a direct quotation
Read the original (Study abstract)

✅ For people with Parkinson’s

This points to the possibility of widening how and where follow-up is delivered while maintaining treatment outcomes. It is particularly relevant to people travelling long distances for DBS programming. It is not a new operation or a treatment proven to stop progression.

It also differs from adaptive DBSDBS that adjusts stimulation using measured brain signals within clinician-set limits. It differs from a clinician remotely changing settings.Learn more, discussed previously. This study concerns clinicians adjusting a device remotely, not a device automatically adjusting itself.

Remote programming requires compatible equipment and a clinical service. This overseas trial does not establish local availability. If you already have DBS, ask whether your device supports remote programming and which appointments still require attendance. Do not cancel or reduce planned care yourself.

Remote programming is still clinician-delivered treatment. Initial in-person programming and continuing follow-up are part of care; people with Parkinson’s do not independently alter their device settings.

🙋 For family and care partners

Useful symptom information still matters even if the consultation format changes. Note movement before and after adjustments, new speech or walking difficulties, and their relationship to medication times.

If remote care is considered, ask whether someone must help with the connection, whom to contact if it fails or symptoms become troublesome, and when an in-person visit is required. A clear contact route and access to in-person assessment matter alongside convenience.

What you can do now

The wrist device and remote DBS programming are different developments. One aims to ease difficulties with hand use; the other explores a different way of continuing an existing treatment.

Rather than changing care because of a headline, describe the task that most troubles you and the burden of follow-up travel. Ask which treatment fits your tremor and whether there are other ways to receive programming after surgery.

ParkinON has explained recent research and a device-launch announcement in plain language. This is information, not individual diagnosis or treatment advice. Confirm local authorization, access and any treatment changes with your clinician.